Literature DB >> 24387787

Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice.

C Zecca1, G A Digesu, P Robshaw, F Puccini, V Khullar, A Tubaro, C Gobbi.   

Abstract

BACKGROUND AND
PURPOSE: Posterior tibial nerve stimulation (PTNS) is an effective treatment option for lower urinary tract symptoms (LUTS) in multiple sclerosis (MS) patients.
METHODS: Patients with MS and LUTS unresponsive to medical treatment received PTNS for 12 weeks after saline urodynamics to evaluate the prevalence of motor, sensory and combined responses during PTNS and to determine whether the type of response can predict treatment outcome. LUTS were also assessed using a 3-day bladder diary, patient perception of bladder condition (PPBC) questionnaire, patient perception of intensity of urgency scale (PPIUS), Kings Health QOL questionnaire (KHQ) and Overactive Bladder Questionnaire (OAB-q) before and after treatment. Patients were considered as "responders" if they reported an improvement >50% in their LUTS according to the PPBC. Sensory, motor and combined sensory/motor responses were compared between responders and non-responders.
RESULTS: Eighty-three patients were included. 61% (51/83) of patients were responders. Sensory, motor and combined sensory/motor responses were found in 64% (53/83), 6% (5/83) and 30% (25/83) of patients respectively. A sensory response alone, or in combination with a motor response, was better associated with a successful outcome than the presence of a motor response alone (P = 0.001).
CONCLUSIONS: A sensory response, either alone or in combination with a motor response, is more frequent and seems to be better associated with a successful outcome of PTNS than motor response alone.
© 2014 The Author(s) European Journal of Neurology © 2014 EFNS.

Entities:  

Keywords:  multiple sclerosis; neuromodulation; percutaneous tibial nerve stimulation; urinary dysfunction

Mesh:

Year:  2014        PMID: 24387787     DOI: 10.1111/ene.12339

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Stimulation of the tibial nerve-a randomised trial for urinary problems associated with Parkinson's-the STARTUP trial.

Authors:  Doreen McClurg; Andrew Elders; Suzanne Hagen; Helen Mason; Jo Booth; Anne-Louise Cunnington; Richard Walker; Katherine Deane; Danielle Harari; Jalesh Panicker; Susan Stratton; Jaclyn McArthur; Ceri Sellers; Marissa Collins
Journal:  Age Ageing       Date:  2022-06-01       Impact factor: 12.782

2.  Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder.

Authors:  Katarina Ivana Tudor; Jai H Seth; Martina D Liechti; Juliana Ochulor; Gwen Gonzales; Collette Haslam; Zoe Fox; Mahreen Pakzad; Jalesh N Panicker
Journal:  Clin Auton Res       Date:  2018-08-03       Impact factor: 4.435

Review 3.  Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis.

Authors:  Chiara Zecca; Letizia Panicari; Giulio Disanto; Paolo Maino; Anand Singh; G Alessandro Digesu; Claudio Gobbi
Journal:  Int Urogynecol J       Date:  2015-08-06       Impact factor: 2.894

Review 4.  Neuromodulation in neurogenic bladder.

Authors:  Melissa T Sanford; Anne M Suskind
Journal:  Transl Androl Urol       Date:  2016-02

5.  Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms.

Authors:  Jai H Seth; Gwen Gonzales; Collette Haslam; Mahreen Pakzad; Arvind Vashisht; Arun Sahai; Charles Knowles; Arthur Tucker; Jalesh Panicker
Journal:  Transl Androl Urol       Date:  2018-12

6.  A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods.

Authors:  Giulia I Lane; Yang Mao-Draayer; Paholo Barboglio-Romo; J Quentin Clemens; Priyanka Gupta; Rod Dunn; Yongmei Qin; Anne P Cameron; John T Stoffel
Journal:  BMC Urol       Date:  2020-05-27       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.